Patient characteristics available during hospital admission
| Total, N (%) | Post-COVID-19 breathlessness | Total | ||
| No | Yes | |||
| Total, N (%) | 611 (49.8) | 615 (50.2) | 1226 | |
| Admission duration, days, median (IQR) | 1225 (99.9) | 7.0 (4.0–14.0) | 9.0 (4.0–22.0) | 8.0 (4.0–17.0) |
| SARS-CoV-2 PCR result | 1137 (92.7) | |||
| Negative | 47 (7.7) | 51 (8.3) | 98 (8.0) | |
| Positive | 522 (85.4) | 517 (84.1) | 1039 (84.7) | |
| Data missing | 42 (6.9) | 47 (7.3) | 89 (7.3) | |
| WHO clinical progression scale | 1226 (100.0) | |||
| WHO class 3–4 | 110 (18.0) | 113 (18.4) | 223 (18.2) | |
| WHO class 5 | 252 (41.2) | 225 (36.6) | 477 (38.9) | |
| WHO class 6 | 136 (22.3) | 120 (19.5) | 256 (20.9) | |
| WHO class 7–9 | 113 (18.5) | 157 (25.5) | 270 (22.0) | |
| Proning during mechanical ventilation | 1102 (89.9) | |||
| No | 466 (76.3) | 426 (69.3) | 892 (72.8) | |
| Yes | 87 (14.2) | 123 (20.0) | 210 (17.1) | |
| Data missing | 58 (9.5) | 66 (10.7) | 124 (10.1) | |
| Pulmonary embolism | 1146 (93.5) | |||
| No | 518 (84.8) | 507 (82.4) | 1025 (83.6) | |
| Yes | 56 (9.2) | 65 (10.6) | 121 (9.9) | |
| Data missing | 37 (6.1) | 43 (7.0) | 80 (6.5) | |
| Coronary thrombosis | 1140 (93.0) | |||
| No | 570 (93.3) | 565 (91.9) | 1135 (92.6) | |
| Yes | <5 | <5 | 5 (0.4) | |
| Data missing | 86 (7.0) | |||
| Antibiotic therapy | 1187 (96.8) | |||
| No | 115 (18.8) | 121 (19.7) | 236 (19.2) | |
| Yes | 477 (78.1) | 474 (77.1) | 951 (77.6) | |
| Data missing | 19 (3.1) | 20 (3.3) | 39 (3.2) | |
| Systemic steroids, oral or i.v. | 1144 (93.3) | |||
| No | 319 (52.2) | 294 (47.8) | 613 (50.0) | |
| Yes | 250 (40.9) | 281 (45.7) | 531 (43.3) | |
| Data missing | 42 (6.9) | 40 (6.5) | 82 (6.7) | |
| Therapeutic dose anticoagulation | 1150 (93.8) | |||
| No | 352 (57.6) | 333 (54.1) | 685 (55.9) | |
| Yes | 220 (36.0) | 245 (39.8) | 465 (37.9) | |
| Data missing | 39 (6.4) | 37 (6.0) | 76 (6.2) | |
Data are presented as n (%) unless otherwise stated. World Health Organization (WHO) clinical progression scale: not requiring continuous supplemental oxygen (levels 3–4); continuous supplemental oxygen only (level 5); continuous positive airway pressure ventilation, bilevel positive airway pressure or high-flow nasal oxygen (level 6); invasive mechanical ventilation, extra-corporeal membrane oxygenation and acute renal replacement therapy (levels 7–9). n<5 and related subtotals have been suppressed. IQR: interquartile range.